Neurosense Therapeutics is trading 11.3% down today at $0.52 as the stock extends its decline without a fresh news catalyst.
- The move comes with no new company-specific headlines or fundamental developments reported this morning, extending a steady drop from last week’s $0.70 level.
- The decline occurs despite a broadly positive biotech sector backdrop, suggesting continued selling pressure in a thinly traded micro-cap name rather than a specific catalyst.